Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma

No abstract is available for this paper.

• Publication year

  2013

• Venue

  European Journal of Clinical Pharmacology

• Publication date

  2013-06-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00228-013-1550-4PMID 23784008
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study

  2013cited by this paper
• Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis

  2013cited by this paper
• The laboratory and the new oral anticoagulants.

  2013cited by this paper
• Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories.

  2013cited by this paper
• Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants

  2013cited by this paper
• Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: Implications for emergency surgery and resuscitation

  2012cited by this paper
• Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy.

  2012cited by this paper
• Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology

  2012cited by this paper
• Impact of dabigatran on a large panel of routine or specific coagulation assays

  2012cited by this paper
• Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents

  2011cited by this paper
• Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement.

  2011cited by this paper
• Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects

  2011cited by this paper
• Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

  2010cited by this paper
• Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays

  2010cited by this paper
• Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor

  2009cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate

  2008cited by this paper
• In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate

  2007cited by this paper
• The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.

  2007cited by this paper

• Putting DOAC Doubts to Bed(Side): Preliminary Evidence of Comparable Functional Outcomes in Anticoagulated and Non-Anticoagulated Stroke Patients Using Point-of-Care ClotPro® Testing

  2025cites this paper
• Viscoelastic Point-of-Care Testing (ClotPro®) to Guide Intravenous Thrombolysis in Acute Ischemic Stroke Patients on DOACs: Replacing History with Hemostasis in a Proof-of-Concept Study

  2025cites this paper
• Effects of dabigatran, rivaroxaban, and apixaban on fibrin network permeability, thrombin generation, and fibrinolysis

  2024cites this paper
• The 2023 WSES guidelines on the management of trauma in elderly and frail patients

  2024cites this paper
• Role of CES1 and ABCB1 Genetic Polymorphisms on Functional Response to Dabigatran in Patients with Atrial Fibrillation

  2024influential citation
• Association between admission prothrombin time activity and hospital readmission in heart failure: a retrospective study.

  2023cites this paper
• Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop

  2022cites this paper
• Hemoclot Thrombin Inhibitor Assay and Expected Peak-Trough Levels of Dabigatran: A Multicenter Study

  2022cites this paper
• DOAC Dipstick Testing Can Reliably Exclude the Presence of Clinically Relevant DOAC Concentrations in Circulation

  2022cites this paper
• Effects of digital processing on repeatability assessment of a multiple reaction monitoring liquid chromatography-tandem mass spectrometry system by ISO 11843-7.

  2022cites this paper
• Direct Oral Anticoagulants: Laboratory Challenges and Antidotes

  2022cites this paper
• Evaluation of DOAC Dipstick Test for Detecting Direct Oral Anticoagulants in Urine Compared with a Clinically Relevant Plasma Threshold Concentration

  2022cites this paper
• терапии ацетилсалициловой кислотой у пациентов с цереброваскулярной патологией in Patients with

  2021cites this paper
• Mechanisms of anticoagulant drugs

  2021cites this paper
• A retrospective study of indications and consequences of monitoring direct oral anticoagulant plasma concentrations on patient care in a university hospital: The Retro-AOD study.

  2021cites this paper
• Monitoring of Aspirin Therapy in Patients with Cerebrovascular Pathology

  2021cites this paper
• Emergency Cardiac Surgery in Patients on Oral Anticoagulants and Antiplatelet Medications

  2021influential citation
• Emergency cardiac surgery in patients on oral anticoagulants and antiplatelet medications.

  2021cites this paper
• Liquid chromatography–tandem mass spectrometry (LC–MS/MS) method for determination of free and total dabigatran in human plasma and its application to a pharmacokinetic study

  2021cites this paper
• Impact of Dabigatran Treatment on Rotation Thromboelastometry

  2021cites this paper
• The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation

  2021cites this paper
• Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants

  2021cites this paper
• Anti-FXa-IIa activity test in Asian and its potential role for drug adherence evaluation in patients with direct oral anticoagulants: a nationwide multi-center synchronization study.

  2020cites this paper
• Effects of rivaroxaban and dabigatran on global hemostasis in patients with atrial fibrillation.

  2020cites this paper
• A chemometric comparison of different models in fluorescence analysis of dabigatran etexilate and dabigatran.

  2020cites this paper
• Analytical verification and comparison of chromogenic assays for dabigatran, rivaroxaban and apixaban determination on BCSXP and STA Compact Max analysers

  2020influential citation
• Major bleeding events in octagenarians associated with drug interactions between dabigatran and P-gp inhibitors

  2019cites this paper
• Removal of dabigatran using sorbent hemadsorption.

  2019cites this paper
• Clinical use and laboratory testing of oral anticoagulation therapy: experience from Finland

  2019cites this paper
• Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban

  2019cites this paper
• Advances in monitoring anticoagulant therapy.

  2019cites this paper
• QUANTIFICATION OF ANTICOAGULANTS DABIGATRAN, RIVAROXABAN, AND PRASUGREL BY CHROMATOGRAPH IC AND SPECTROMETRIC TECHNIQUES – REVIEW

  2019cites this paper
• Adherence to dabigatran etexilate in atrial fibrillation patients intended to undergo electrical cardioversion

  2019cites this paper
• Major publications in the critical care pharmacotherapy literature: January–December 2017

  2018cites this paper
• Real-Life Peak and Trough Dabigatran Plasma Measurements Over Time in Hospitalized Geriatric Patients with Atrial Fibrillation

  2018cites this paper
• HPLC-MS/MS Method for Determining Dabigatran in Human Blood Serum

  2018cites this paper
• Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START‐Laboratory Register

  2018cites this paper
• International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

  2018cites this paper
• The effect of dabigatran on thrombin generation and coagulation assays in rabbit and human plasma.

  2018cites this paper
• The anticoagulant effect of therapeutic levels of dabigatran in atrial fibrillation evaluated by thrombelastography (TEG®), Hemoclot Thrombin Inhibitor (HTI) assay and Ecarin Clotting Time (ECT)

  2018influential citation
• Methods to monitor the therapy oral anticoagulants: the current problems.

  2018cites this paper
• Fatal Adverse Event with Dabigatran in Elderly Patient with Reduced Kidney Function

  2018cites this paper
• VARNOST IN UČINKOVITOST NOVIH ANTIKOAGULACIJSKIH ZDRAVIL PRI BOLNIKIH Z ATRIJSKO FIBRILACIJO – PROSPEKTIVNA KLINIČNA RAZISKAVA

  2018cites this paper
• Does type 2 diabetes affect the on-treatment levels of direct oral anticoagulants in patients with atrial fibrillation?

  2018cites this paper
• Comprehensive characteristics of the anticoagulant activity of dabigatran in relation to its plasma concentration.

  2018cites this paper
• Coagulation Test Interpretation in a Patient Taking Direct Oral Anticoagulant Therapy.

  2018cites this paper
• Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time.

  2018cites this paper
• Rapid determination of anticoagulating effects of dabigatran in whole blood with rotational thromboelastometry and a thrombin‐based trigger

  2018cites this paper
• Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis

  2018cites this paper
• Differences between activities of coagulation factors after one month of therapy with different direct oral anticoagulant in pulmonary embolism patients

  2018cites this paper
• The dose individualisation of oral anticoagulants

  2018cites this paper
• Management of the Trauma Patient on Direct Oral Anticoagulants

  2018cites this paper
• Measurement and reversal of the direct oral anticoagulants.

  2017cites this paper
• Real life dabigatran and metabolite concentrations, focused on inter-patient variability and assay differences in patients with atrial fibrillation

  2017cites this paper
• Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review

  2017cites this paper
• [Renal function and plasma dabigatran level measured at trough by diluted thrombin time assay].

  2017cites this paper
• Whole blood coagulation assays ROTEM and T-TAS to monitor dabigatran treatment.

  2017cites this paper
• Laboratory Monitoring of Direct Oral Anticoagulants

  2017cites this paper
• Laboratory Assessment of Direct Oral Anticoagulants

  2017cites this paper
• Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study

  2016cites this paper
• Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or useless

  2016cites this paper
• An update on laboratory measurements of Dabigatran: Smart specific and calibrated dedicated assays for measuring anti-IIa activity in plasma.

  2016cites this paper
• Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation

  2016cites this paper
• Dabigatran en plasma: tiempos de trombina diluido, Ecarin y veneno de víbora de Russell diluido

  2016cites this paper
• Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used?

  2016cites this paper
• Reversal of direct oral anticoagulants: a practical approach.

  2016cites this paper
• Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma.

  2016cites this paper
• Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations

  2016cites this paper
• Dosage plasmatique de quatre anticoagulants directs par UHPLC/DAD

  2016cites this paper
• Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure

  2016cites this paper
• Risk management of direct oral anticoagulant administration: An approach from the clinical laboratory

  2016cites this paper
• Direct Oral Anticoagulants: Monitoring Anticoagulant Effect.

  2016cites this paper
• Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication

  2016cites this paper
• Development and Validation of RP-UPLC Method for the Determination of Process and Degradant Impurities Present in Dabigatran Etexilate Mesylate Capsules Using High Strength Silica-T3 Sorbent Column

  2016cites this paper
• Real‐world variability in dabigatran levels in patients with atrial fibrillation: reply

  2015cites this paper
• Monitoring anticoagulant therapy with new oral agents.

  2015cites this paper
• Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study.

  2015cites this paper
• Relationship between plasma dabigatran concentration and activated partial thromboplastin time in Japanese patients with non‐valvular atrial fibrillation

  2015cites this paper
• From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples.

  2015cites this paper
• Determination of dabigatran in plasma, serum, and urine samples: comparison of six methods

  2015cites this paper
• Patients' Serum and Urine as Easily Accessible Samples for the Measurement of Non–Vitamin K Antagonist Oral Anticoagulants

  2015cites this paper
• Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis.

  2015cites this paper
• Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations

  2015influential citation
• Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?

  2015cites this paper
• Dabigatran for the prevention and treatment of thromboembolic disorders

  2015cites this paper
• Laboratory Testing in the Era of Direct or Non–Vitamin K Antagonist Oral Anticoagulants: A Practical Guide to Measuring Their Activity and Avoiding Diagnostic Errors

  2015cites this paper
• Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review

  2015cites this paper
• Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study.

  2015cites this paper
• Dabigatran Concentration: Variability and Potential Bleeding Prediction In “Real–Life” Patients With Atrial Fibrillation

  2015cites this paper
• Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives

  2015cites this paper
• Is thrombin time too sensitive to dabigatran anticoagulation for clinical decision making in the setting of acute hemorrhage?

  2015cites this paper
• Real‐world variability in dabigatran levels in patients with atrial fibrillation: comment

  2015cites this paper
• Monitoring and reversal of direct oral anticoagulants.

  2015cites this paper
• A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage

  2015cites this paper
• The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders

  2015cites this paper
• Anticoagulation Management in the Emergency Department

  2015cites this paper
• IDENTIFICATION OF DABIGATRAN ETEXILATE MAJOR DEGRADATION PATHWAYS BY LIQUID CHROMATOGRAPHY COUPLED TO MULTI STAGE HIGH-RESOLUTION MASS SPECTROMETRY

  2015cites this paper
• Namur Real-world variability in dabigatran levels in patients with atrial fibrillation

  2015cites this paper
• RENAL FUNCTION IN RELATION TO GENTAMICIN AND DABIGATRAN CLEARANCE AND DOSING

  2014cites this paper
• A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time.

  2014cites this paper